How synapses keep their edge
In a nutshell
Munc13-1, also known as Unc-13 homolog A in humans, is a core active-zone protein that prepares synaptic vesicles for calcium (Ca2+)-triggered membrane fusion.
Munc13-1 integrates lipid and cytosolic Ca2+ signals via its C1 and C2B domains to tune synaptic strength and short-term plasticity, including post-tetanic potentiation (PTP).
TrkB signaling via PLC-γ activates Munc13-1 through DAG generation.
In a DAG-dependent manner, Munc13-1 shifts vesicles towards a tightly primed state, thereby boosting basal strength, but impairing sustained transmission and abolishing PTP.
Every thought, movement, or perception depends on communication between neurons at specialized contact points called synapses. At these junctions, neurotransmitter-filled vesicles must be prepared before they fuse with the membrane and release their contents. This step – termed vesicle priming – determines how effectively synapses transmit information and adapt during activity.
Researchers at the Max Planck Institute (MPI) for Multidisciplinary Sciences, the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), the Howard Hughes Medical Institute, the University of Utah, and Stanford University, have now identified the presynaptic protein Munc13-1 as a key control point linking intracellular lipid and Ca2+ signals to vesicle readiness and synaptic performance.
A useful analogy is a shipping dock. Synaptic vesicles are cargo packages, and Munc13-1 acts as the dock supervisor organizing them for rapid dispatch. Some packages wait in a staging area, while others are already on the conveyor belt, ready to be shipped when the signal arrives. Transmission efficiency depends on how many vesicles are immediately ready and how quickly new ones are moved into position as demand rises.
Stronger response to single action potentials
A research team led by Holger Taschenberger at the MPI, together with Noa Lipstein from the FMP and Max Plank colleague Nils Brose, introduced a conditional knock-in point mutation (Munc13-1 H567K) that disrupts diacylglycerol (DAG) sensing. Using high-resolution electrophysiology and super-resolution microscopy at the calyx of Held synapse, the scientists found that this mutation shifts more vesicles into the release-ready state at rest, thereby strengthening responses to single action potentials.
However, this advantage comes at a cost. During repetitive stimulation, release-ready vesicles cannot be replenished fast enough. Like a dock dispatching too many packages without restocking, the synapse rapidly exhausts its supply. Transmission weakens more quickly and recovery after intense activity is slower.
The researchers further showed that presynaptic TrkB signaling enhances synaptic strength through Munc13-1, revealing the mechanism by which extracellular signals control vesicle priming by modifying intracellular DAG and Ca2+ levels. Importantly, the Munc13-1 H567K mutation strongly reduces post-tetanic potentiation (PTP) – a transient increase in strength that normally follows intense bursts of activity.
Together, these findings identify Munc13-1 as a molecular integrator balancing immediate performance with sustained transmission during ongoing demand.
Mutations in UNC13A gene are linked to neurodevelopmental disorders and to neurodegeneration
Beyond its fundamental role in synaptic function, Munc13-1 has emerged as a major factor in human health. Variants in the human UNC13A gene, which encodes the human protein, have been linked to neurodevelopmental disorders and to neurodegeneration. By revealing how Munc13-1 controls vesicle priming and synaptic plasticity, this work provides a framework for understanding how disease-associated UNC13A mutations alter synaptic function. In the long term, such insights may help guide the development of therapies aimed at restoring normal synaptic signaling. (ht)
This work was supported by the German Research Foundation (SFB1286-A9, Br1107/15; N.B.), German Research Foundation (SFB1286-A11; N.L.), German Research Foundation (Excellence Strategy EXC-2049–390688087; N.L.), Alexander von Humboldt Foundation (E.M.J.), Howard Hughes Medical Institute (HHMI; E.M.J. and T.S.), National Institutes of Health (NIH; R01 NS034307; E.M.J.), National Science Foundation (NSF; Neuronex 2014862; E.M.J.), and Target ALS Foundation (Industry-Led Collaborative Consortium; N.L.).